T
Torben Plesner
Researcher at University of Southern Denmark
Publications - 205
Citations - 11134
Torben Plesner is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Daratumumab & Multiple myeloma. The author has an hindex of 45, co-authored 186 publications receiving 9295 citations. Previous affiliations of Torben Plesner include University of Copenhagen & Finsen Laboratory.
Papers
More filters
Journal ArticleDOI
Response to: Interference of daratumumab on the serum protein electrophoresis
Christopher R. McCudden,Amy Axel,Dominique Slaets,Thomas Dejoie,Pamela L. Clemens,Sandy Frans,Jaime Bald,Torben Plesner,Joannes F M Jacobs,Niels W.C.J. van de Donk,Philippe Moreau,Jordan M. Schecter,Tahamtan Ahmadi,A. Kate Sasser +13 more
TL;DR: Responses to the intervention of daratumumab on the serum protein electrophoresis are described in Clinical Chemistry and Laboratory Medicine, 55(2), e29-e30.
Journal ArticleDOI
An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
Jonathan L. Kaufman,Hang Quach,Rachid Baz,Annette Juul Vangsted,Shir-Jing Ho,Simon J. Harrison,Torben Plesner,Philippe Moreau,Simon Gibbs,Eva Medvedova,Muhammad Jalaluddin,Jeremy A. Ross,Leanne Lash Fleming,Yan Luo,Nizar J. Bahlis +14 more
TL;DR: Bahlis et al. as mentioned in this paper proposed a combination of daratumumab (D), an anti-CD38 antibody, bortezomib (V), a proteasome inhibitor (PI), and dexamethasone (d) for the treatment of multiple myeloma.
Journal ArticleDOI
Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Thierry Facon,Shaji Kumar,Katja Weisel,Saad Usmani,Philippe Moreau,Torben Plesner,Robert Z. Orlowski,Nizar J. Bahlis,Supratik Basu,Hareth Nahi,Cyrille Hulin,Hang Quach,Michael O'Dwyer,Aurore Perrot,Christopher P. Venner,Noopur Raje,Mourad Tiab,Margaret Macro,Laurent Frenzel,Xavier Leleu,Huiling Pei,Robin Carson,Fredrik Borgsten,Hartmut Goldschmidt +23 more
TL;DR: Facon et al. as mentioned in this paper evaluated DARA in patients with newly diagnosed multiple myeloma (NDMM) and as monotherapy and in combination with standard of care for patients with relapsed/refractory MML.
Journal ArticleDOI
Immunostaining of skin biopsy adds no diagnostic value in MGUS-associated peripheral neuropathy
TL;DR: Examination of skin biopsies for immunoglobulin deposition does not add significant diagnostic value in the evaluation of neuropathies suspected to be caused by MGUS or WM, and might merely be an epiphenomenon secondary to high IgM blood levels.
Journal ArticleDOI
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study
Torben Plesner,Hendrik-Tobias Arkenau,Monique C. Minnema,Mario Boccadoro,Philippe Moreau,James D. Cavenagh,Aurore Perrot,Jacob P. Laubach,Tahamtan Ahmadi,Carla de Boer,Diana Chen,Christopher Chiu,Jordan M. Schecter,Paul G. Richardson +13 more
TL;DR: The final safety and efficacy results of the GEN503 study of DARA in combination with lenalidomide and dexamethasone with approximately 3-year follow-up in patients with RRMM are provided.